Login to Your Account

Chasing Botox's Success

Biotechs in Aesthetics Space Mixing Science, Consumerism

By Jennifer Boggs

Monday, April 25, 2011
In less than two months, Fibrocell Sciences Inc.'s LaViv (azficel-T) could become the second FDA-approved autologous cell therapy, following Dendreon Corp.'s prostate cancer vaccine Provenge (sipuleucel-T) last year. But the Exton, Pa.-based biotech isn't aiming for the medical market.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription